105 related articles for article (PubMed ID: 1422499)
1. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.
Collins RH; Rogers ZR; Bennett M; Kumar V; Nikein A; Fay JW
Bone Marrow Transplant; 1992 Oct; 10(4):391-5. PubMed ID: 1422499
[TBL] [Abstract][Full Text] [Related]
2. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Delage R; Ritz J; Anderson KC
Hematol Oncol Clin North Am; 1990 Apr; 4(2):369-88. PubMed ID: 2182597
[TBL] [Abstract][Full Text] [Related]
3. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
Gale RP; Horowitz MM
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
[TBL] [Abstract][Full Text] [Related]
5. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
6. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
7. [Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation].
Kanamori H; Sasaki S; Ueda S; Yamazaki E; Tamura T; Harano H; Matsuzaki M; Ogawa K; Mohri H; Okubo T
Rinsho Ketsueki; 1997 Aug; 38(8):643-6. PubMed ID: 9311269
[TBL] [Abstract][Full Text] [Related]
8. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
11. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
14. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
15. Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin A discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation.
Suzuki R; Taji H; Iida S; Miura K; Kagami Y; Ogura M; Yatabe Y; Nakamura S; Seto M; Morishima Y
Bone Marrow Transplant; 1997 Oct; 20(7):615-7. PubMed ID: 9337067
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
Miyamura K; Barrett AJ; Kodera Y; Saito H
Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of the CD45RO(+) and CD20(+) lymphoid marrow population following allogeneic bone marrow transplantation for Ph(+) CML.
Thiele J; Kvasnicka HM; Beelen DW; Welter A; Schneider S; Leder LD; Schaefer UW
Bone Marrow Transplant; 2001 Feb; 27(4):425-31. PubMed ID: 11313672
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
20. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]